Systemic Immune-inflammation Index is a Promising Noninvasive Marker to Predict Survival of Lung Cancer: A Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2019 Jan 18

PMID 30653090

Citations 52

Authors

Yi Zhang

Bo Chen

Lijuan Wang

Rong Wang

Xianjin Yang

Affiliations

Soon will be listed here.

Abstract

Background: The prognostic value of pretreatment systemic immune-inflammation index (SII) in lung cancer has yet to be fully established.

Methods: Relevant articles were obtained by performing a systematic search. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were used to assess the relationship between SII index and overall survival (OS) in lung cancer; the OS was calculated from the time of cancer diagnosis to the date of death due to any cause or to the last date of follow-up.

Results: In total, 2786 patients with lung cancer from 7 studies were included in this meta-analysis. The median thresholds to define high SII was 640 (range 395.4-1600) in the analyzed studies. The pooled HR for OS was 1.77 (95% CI: 1.54-2.00, P < .001), suggesting that the patients with a high SII score had a worse OS. In addition, results from subgroup meta-analysis showed the significant prognostic significance of SII in lung cancer. Especially, the predictive value of SII was significant in the multivariable model for NSCLC (HR: 1.97, 95% CI: 1.69-2.25, P < .001; 5 studies, 1746 patients), and SCLC (HR: 1.38, 95% CI: 1.02-1.85, P < .001; 1 study, 919 patients).

Conclusion: Our data suggest that high SII index indicates poor survival rate in lung cancer. Further researches are warranted to verify the significance of SII index in clinical practice.

Citing Articles

Neutrophil-to-lymphocyte, platelet-to-lymphocyte ratios and systemic immune-inflammation index in patients with post-traumatic stress disorder.

Yontar G, Mutlu E BMC Psychiatry. 2024; 24(1):966.

PMID: 39741243 PMC: 11686920. DOI: 10.1186/s12888-024-06439-y.

The Prognostic Value of Systemic Immune-Inflammation Index Supporting Age-Adjusted Charlson Comorbidity Index in Non-Small Cell Lung Cancer Patients with First-Line Platinum-Based Chemotherapy.

Sheng Y, Zhu Q, Dai Q, Gao Y, Bai Y, Liu M Int J Gen Med. 2024; 17:5837-5848.

PMID: 39669219 PMC: 11634787. DOI: 10.2147/IJGM.S486674.

Prognostic value of the systemic immune-inflammation index in lung cancer patients receiving immune checkpoint inhibitors: A meta-analysis.

Yang Y, Li J, Wang Y, Luo L, Yao Y, Xie X PLoS One. 2024; 19(11):e0312605.

PMID: 39485761 PMC: 11530041. DOI: 10.1371/journal.pone.0312605.

The role of systemic immune-inflammatory index in predicting contrast-induced nephropathy in non-ST-segment elevation myocardial infarction cases.

Tezen O, Hayiroglu M, Pay L, Yumurtas A, Keskin K, Cetin T Biomark Med. 2024; 18(21-22):937-944.

PMID: 39469834 PMC: 11633407. DOI: 10.1080/17520363.2024.2415284.

Prognostic and clinicopathological significance of systemic immune-inflammation index in upper tract urothelial carcinoma: a meta-analysis of 3911 patients.

Yu Z, Xiong Z, Ma J, Du P, Wang S, Liu J Front Oncol. 2024; 14:1342996.

PMID: 38947894 PMC: 11211359. DOI: 10.3389/fonc.2024.1342996.

References

Minami S, Ihara S, Kim S, Yamamoto S, Komuta K . Lymphocyte to Monocyte Ratio and Modified Glasgow Prognostic Score Predict Prognosis of Lung Adenocarcinoma Without Driver Mutation. World J Oncol. 2018; 9(1):13-20. PMC: 5862078. DOI: 10.14740/wjon1084w. View

Leblanc R, Houssin A, Peyruchaud O . Platelets, autotaxin and lysophosphatidic acid signalling: win-win factors for cancer metastasis. Br J Pharmacol. 2018; 175(15):3100-3110. PMC: 6031885. DOI: 10.1111/bph.14362. View

Hong X, Cui B, Wang M, Yang Z, Wang L, Xu Q . Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer. Tohoku J Exp Med. 2015; 236(4):297-304. DOI: 10.1620/tjem.236.297. View

Tong Y, Tan J, Zhou X, Song Y, Song Y . Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J Transl Med. 2017; 15(1):221. PMC: 5664920. DOI: 10.1186/s12967-017-1326-1. View

Lu H, Jiang Z . Advances in antibody therapeutics targeting small-cell lung cancer. Adv Clin Exp Med. 2018; 27(9):1317-1323. DOI: 10.17219/acem/70159. View

Fan L, Wang R, Chi C, Cai W, Zhang Y, Qian H . Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients. Prostate. 2017; 78(4):250-256. DOI: 10.1002/pros.23465. View

Lerman I, Hammes S . Neutrophil elastase in the tumor microenvironment. Steroids. 2017; 133:96-101. PMC: 5870895. DOI: 10.1016/j.steroids.2017.11.006. View

Bareschino M, Schettino C, Rossi A, Maione P, Sacco P, Zeppa R . Treatment of advanced non small cell lung cancer. J Thorac Dis. 2012; 3(2):122-33. PMC: 3256511. DOI: 10.3978/j.issn.2072-1439.2010.12.08. View

Guo D, Zhang J, Jing W, Liu J, Zhu H, Fu L . Prognostic value of systemic immune-inflammation index in patients with advanced non-small-cell lung cancer. Future Oncol. 2018; 14(25):2643-2650. DOI: 10.2217/fon-2018-0285. View

10.

Govindan R, Bogart J, Vokes E . Locally advanced non-small cell lung cancer: the past, present, and future. J Thorac Oncol. 2008; 3(8):917-28. DOI: 10.1097/JTO.0b013e318180270b. View

11.

Liu D, Jin J, Zhang L, Li L, Song J, Li W . The Neutrophil to Lymphocyte Ratio May Predict Benefit from Chemotherapy in Lung Cancer. Cell Physiol Biochem. 2018; 46(4):1595-1605. DOI: 10.1159/000489207. View

12.

Zhong J, Huang D, Chen Z . Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017; 8(43):75381-75388. PMC: 5650428. DOI: 10.18632/oncotarget.18856. View

13.

Wang K, Diao F, Ye Z, Zhang X, Zhai E, Ren H . Prognostic value of systemic immune-inflammation index in patients with gastric cancer. Chin J Cancer. 2017; 36(1):75. PMC: 5596912. DOI: 10.1186/s40880-017-0243-2. View

14.

Toda M, Tsukioka T, Izumi N, Komatsu H, Okada S, Hara K . Platelet-to-lymphocyte ratio predicts the prognosis of patients with non-small cell lung cancer treated with surgery and postoperative adjuvant chemotherapy. Thorac Cancer. 2017; 9(1):112-119. PMC: 5754286. DOI: 10.1111/1759-7714.12547. View

15.

Contursi A, Sacco A, Grande R, Dovizio M, Patrignani P . Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting. Cell Mol Life Sci. 2017; 74(19):3491-3507. PMC: 11107532. DOI: 10.1007/s00018-017-2536-7. View

16.

Albany C . Systemic immune-inflammation index in germ-cell tumours: search for a biological prognostic biomarker. Br J Cancer. 2018; 118(6):761-762. PMC: 5886128. DOI: 10.1038/bjc.2018.7. View

17.

Chovanec M, Cierna Z, Miskovska V, Machalekova K, Kalavska K, Rejlekova K . Systemic immune-inflammation index in germ-cell tumours. Br J Cancer. 2018; 118(6):831-838. PMC: 5877428. DOI: 10.1038/bjc.2017.460. View

18.

Xia H, Sun Z, Deng L, Zhu D, Wang D . Prognostic Significance of the Preoperative Lymphocyte to Monocyte Ratio in Patients With Stage I Non-Small Cell Lung Cancer Undergoing Complete Resection. Cancer Invest. 2016; 34(8):378-84. DOI: 10.1080/07357907.2016.1213276. View

19.

Chou C, Li M . Re(de)fining Innate Lymphocyte Lineages in the Face of Cancer. Cancer Immunol Res. 2018; 6(4):372-377. PMC: 7372303. DOI: 10.1158/2326-6066.CIR-17-0440. View

20.

Kang K, Efird J, Sharma N, Yang M, Dowlati A, Linden P . Prognostic potential of neutrophil-to-lymphocyte ratio and lymphocyte nadir in stage III non-small-cell lung cancer. Future Oncol. 2017; 13(16):1405-1414. DOI: 10.2217/fon-2017-0045. View